Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 22:01 UTC. Every row links to its source record.

Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

NCT04746924 · BeiGene · PHASE3 · terminated · last registry update 2026-05-12 · Non-small cell lung cancer · Decision brief

No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.

What was said, and by whom

Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.

Kind	Quote	Our category	Source
Stated	“This decision was conducted by the sponsor based on lack of efficacy and not driven by safety concerns.”	Open Targets' class: negative	Registry record, BeiGene

Also happening at the time. Not shown to be a cause.

Registry events on other trials of drugs against PDCD1 in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.

What is not public

Internal portfolio and board discussions
Unpublished trial data and interim analyses
Terms of any partner or licence decision